Drugs / XAV939
XAV939
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07396376 | Nov 2025 → Jun 2026 overdue | ulcer of lower limbs | Eluciderm Inc | Recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | XAV939 | “ELU42 combines a tankyrase inhibitor (XAV939) with a novel derivatized hyaluronic acid excipient (DHA77) and is applied as a topical spray to the index ulcer.” NCT07396376 ↗ |
| Known as | 284028-89-3 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1086580 ↗ |
| Known as | NVP-XAV939 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1086580 ↗ |
| Action | Inhibit | “tankyrase inhibitor (XAV939)” NCT07396376 ↗ |
| Modality | Small molecule | — CHEMBL1086580 ↗ |